DAM
APTO

DLD Asset Management’s Aptose Biosciences, Inc. APTO Stock Holding History

DLD Asset Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-446
Closed -$1.14M – 108
2019
Q4 		$1.14M Buy
+446
New +$581K 0.06% 73

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DLD Asset Management's APTO Position: Q1 2020 in Review

DLD Asset Management sold out of Aptose Biosciences, Inc. (APTO) in Q1 2020, closing a stake of 446 shares — an estimated $1.14M sold.

DLD Asset Management first reported a position in APTO in Q4 2019 and held it in 1 quarter. The position peaked at $1.14M in Q4 2019. 51 funds tracked by Wall St. Rank hold APTO as of Q1 2020.

  • DLD Asset Management reported no remaining Aptose Biosciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • DLD Asset Management sold 446 Aptose Biosciences, Inc. shares in Q1 2020, an estimated $1.14M.
  • DLD Asset Management first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 1 quarter.
  • DLD Asset Management's Aptose Biosciences, Inc. position peaked at $1.14M in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2020.

Based on DLD Asset Management's 13F filing for Q1 2020, filed 14 May 2020.